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Abstract 
A higher risk of atherosclerosis and related cardiovascular disease has been observed 
in patients with rheumatoid arthritis. Anti-TNFα monoclonal antibodies are used for 
the treatment of resistant rheumatoid arthritis resulting in inhibition of TNFα binding 
to cellular receptors that activate disease-associated pro-inflammatory pathways. The 
effect of TNFα inhibition on the lipoprotein pattern may provide information on the 
risk of atherosclerosis in these patients. In the present study the lipoprotein profiles of 
patients with rheumatoid arthritis have been examined before and after treatment with 
anti-TNFα. 85 patients (76 women, 89%) with established RA (disease duration ≥5 
years), mean age 57 ± 12 (68% with RF positive), no known cardiovascular disease, 
thyroid disorder and thyroid disorder’s treatment with DMARDs and not receiving 
biological agents as treatment, were divided into 2 groups, those who had DAS28> 3.2 
(43 patients) who were additionally reserved anti-TNFα biological factor for ≥12 
months and those who had DAS28≤3.2 (42 patients) who continued DMARD 
treatment and were monitored at the same time as a control group. Samples were 
taken at two times with a difference of ≥12 months. Separation of the lipoprotein 
subtypes was done by 4% polyacrylamide native gel electrophoresis. Two LDL 
(LDLA and LDL B) and six HDL (HDL1, HDL2a, HDL2b, HDL3a, HDL3b and 
HDL3c) subtypes were characterized. In patients receiving DMARDs, a decrease in 
the LDL-B subtype by 11.9% (p = 0.014) and an increase in HDL-3c by 2.38% (p = 
0.049) were observed. In PA patients receiving anti-TNFα, a reduction in the LDL-B 
subtype was observed by 2.33% (p = 0.005), LDL-A by 2.33% (p = 0.0001), HDL3a 
by 11.63% = 0.072) and HDL3c by 4.65% (p = 0.035). In RA patients receiving anti-
TNFα, a reduction in the LDL-B fractions was observed by 2.33% (p = 0.005), LDL-
A by 2.33% (p = 0.0001), HDL3a by 11.63% = 0.072) and HDL3c by 4.65% (p = 
0.035). 
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Introduction  
The high levels of systemic 
inflammation have been associated 
with increased cardiovascular disease 
(CVD). Rheumatoid arthritis (RA) is a 
systemic autoimmune disease 
associated with a significantly 
increased of atherosclerotic risk 
(Charles-Schoeman et al., 2015; 
Charles-Schoeman et al., 2012) 
which remains the leading world-wide 
cause of morbidity and mortality 
(O'Neill et al., 2015). Also, lipids have 
been correlated with atherosclerosis. 
LDL and HDL levels have been 
characterized as the most important 
indicators of coronary heart disease 
(CHD) risk. LDL has been associated 
with coronary artery disease (CAD) by 
numerous epidemiological studies 
(Alabakovska et al., 2004) and large-
size LDL are associated with an 
increased risk of CHD (Babiak and 
Rudel, 1987). In addition, research and 
clinical data have showed the anti-
atherosclerotic effects of HDL via 
reverse cholesterol transport (O’Neil et 
al., 2015). 
Nowadays research is focused on 
subtypes of lipoproteins and their role 
in cardiovascular diseases. According 
to bibliography, LDL subtypes were 
classified as phenotype A (≥25.5 nm) 
or phenotype B (<25.5 nm) and HDL 
subtypes as HDL1(>12.00 nm), 
HDL2b (9.70–12.00 nm) and HDL2a 
(8.80–9.69 nm), HDL3a (8.20–8.79 
nm), HDL3b (7.80–8.19 nm) and 
HDL3c (7.20– 7.79 nm) particles, as 
described previously (Vekic et al., 
2007).  
RA patients receive disease-modifying 
antirheumatic drugs (DMARDs), 
which reduce the signs and symptoms 
of the disease. While several RA 
patients respond to DMARDs, others 
need different treatments because RA 
symptoms remain active. The use of 
TNFα inhibitors in RA treatment was a 
revolution in treatment options of 
chronic inflammatory diseases 
(Kleinert et al., 2012).  TNFα plays a 
central role in this inflammatory 
disease as this cytosine plays an 
extremely central role in driving 
inflammation (Visvanathan et al., 
2010). Differences in expression of 
TNFα level have been observed in 
synovial fluid and the synovium of 
patients with RA. The effects of anti-
TNFα monoclonal antibodies are 
partially dependent on synovial TNFα 
expression and infiltration by TNFα-
producing inflammatory cells 
(Wijbrandts et al., 2008). Anti-TNFα 
binds to TNFα and inhibits its binding 
to the cell receptors abolishing its pro-
inflammatory effect. In the present 
study the lipoprotein profiles of 
patients with rheumatoid arthritis have 
been examined before and after 
treatment with anti-TNFα (Ma and Xu, 
2012).  
Aim of this study is to determine the 
possible changes in the administration 
of anti-TNFα drugs to lipoprotein 
subtypes in patients suffering from 
rheumatoid arthritis. The effect of anti-
TNFα on lipoprotein subtypes can be 
associated with cardiovascular diseases 
that often appear to occur in patients 
with rheumatoid arthritis. Thus, 
knowing the effect of anti-TNFα on 
patients' lipidemic profile, we can 
determine the role of this agent in the 
development of atherosclerosis in 
patients with rheumatoid arthritis. 
 
Methods   
Patients Criteria  
85 patients (76 women, 89%) with 
established RA (mean disease 
duration≥5 yrs), mean age 
57yrs(SD:12yrs), without known 
cardiovascular disease, D/M and 
thyroid disorders, on sDMARD (MTX, 
LEF, SSZ, low dose prednisolone or 
combination) and naive to biologic 
treatment, were divided into two 
groups. Patients with DAS28>3,2 (43 
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Figure 1: Electrophoresis of plasma samples. Τhe figure depicts the different subtypes of 
lipoproteins of eight plasma samples in a Native Polyacrylamide gel electrophoresis (PAGE) 
of 4% concentration. 
 
patients), who took anti-TNFα drugs        
for ≥12 months were group one and 
patients with DAS28≤3,2 (42 patients) 
who continued the previous treatment 
with DMARDs were the control group.  
Samples 
Blood samples of 85 patients were 
collected in EDTA vacutainers and 
plasma was separated by centrifugation 
at 2000rpm. The plasma samples were 
stored at -80°C. Before use, the 
samples were diluted with 
electrophoresis buffer in a dilution one 
to four and prestained overnight with 
Sudan Black B, a dye which is used to 
stain lipoproteins, by mixing 20μl of 
diluted plasma and 20 μl of Sudan 
Black Band.  
Electrophoresis 
Native PAGE (polyacrylamide gel) 
with 4% density was used for the 
separation of lipoproteins subtypes 
with a 2% stacking gel. 4% 
polyacrylamide gels were prepared by 
mixing 4880 μl H2O, 1070 μl 
Acrylamide mix 30% (29% 
Acrylamide / 1% Bis acrylamide), 
2000 μl Tris 1,5M  pH8,8, 80 μl APS 
10% and 8 μl TEMED (Singh et al., 
2008). 20μl of the pre-stained samples 
and 20 μl of standard solution were 
loaded into wells for electrophoresis. 
The standard solution contained a 
 
 
protein mixture of Thyroglobulin 
(Molecular weight (Mr) 669000), 
Ferritin (Mr 440 000), Catalase (Mr 
232 000), Lactate dehydrogenase (Mr 
140000) Albumin (Mr 66000). The 
electrophoresis took place at 4°C with 
TBE buffer (90mM Tris base, 80mM 
Boric acid, 3mM EDTA, pH 8.3). The 
samples were run for 2h at 100V. 
Then, the gels were stained in 
Coomasie brilliant blue for 1h and de-
stained with 40% methanol and 10% 
acetic acid.  
Statistical Method 
Statistical analyses were performed 
using GraphPad InStat3. The results 
collected after electrophoresis were 
analyzed with a two-parameter table 
and their statistical significance was 
examined with Fisher's exact test. A p 
value of <0.05 was considered to 
indicate statistical significance.  
 
Results 
The RA patients on DMARDs had a 
percent reduction of LDL-B subtype 
by 11.9% (p=0.014), but a significant 
increase of HDL-3c subtype by 2.38% 
(p=0.049). In the RA patients who took 
TNFα inhibitors, a prominent percent 
decrease of the more lipoprotein 
subtypes was observed.  LDL-B 
subtype decreased by 2.33% 
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Diagram 1: Lipoproteins subtype frequency pre and post anti-TNFα drugs treatment.  The 
diagram shows the redaction of LDL-A, LDL-B, HDL3a and HDL3c subtypes after anti-
TNFα treatment. 
 
(p=0.005), LDL-A subtype decreased 
by 2.33% (p=0.0001), HDL3a 
decreased subtype by 11.63% 
(p=0.072) and HDL3c subtype 
decreased by 4.65% (p=0.035).   
 
Conclusion 
The aim of the study was to determine 
the effect of anti-TNFα agent on 
patients' lipoprotein subtypes, as it can 
be used as a medicine to combat the 
symptoms of rheumatoid arthritis. 
Patient plasma was studied before and 
after administration of anti-TNFα and 
changes in lipoprotein subtypes were 
observed. 
Anti-TNFα acts competitively by 
blocking the binding of TNFα, which 
is designated as an indicator of 
inflammation. Administration of anti-
TNFα leads to the reduction of 
proinflammatory cytokines and 
chemokines that attract cells to the site 
of inflammation and lowering 
inflammation levels locally. In 
advance, some reports have described 
the effect of TNFα on lipoprotein 
metabolism and support that its 
elevated levels affect hepatic lipid 
metabolism, increasing de novo fatty 
acid synthesis and triglyceride 
 
 
concentration in plasma (Qin et al., 
2007).  
The effect of anti-TNFα on 
lipoproteins is unknown, so the agent 
of lipoprotein metabolism that is 
affected by its administration cannot be 
accurately determined. Some studies 
suggest that an increase of TNFα 
concentration reduces the lipoprotein 
lipase activity which plays a role in the 
conversion of both VLDL lipoproteins  
to LDL lipoproteins and HDL2 
subtypes to HDL3 subtypes and vice 
versa (Levy et al., 2003).  
Cardiovascular events associated with 
rheumatoid arthritis include 
predisposition for atherosclerosis and 
endothelial dysfunction, which results 
in coronary artery disease (CAD), 
stroke, congestive heart failure and 
peripheral arterial disease. Studies 
which test the effect of anti-TNFα on 
cardiovascular disease have led to the 
conclusion that the risk of 
cardiovascular disease is lower in 
patients with rheumatoid arthritis, 
treated with anti-TNFα. This is also 
consistent with the assumption that 
inflammation contributes to the 
development of cardiovascular events  
(Jacobsson et al., 2005).  
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Treatment with anti-TNFα reduces the 
chances of developing atherosclerosis 
by reducing overall concentration of 
LDL lipoproteins, a marker is 
characterized as a good prognostic 
indicator for the occurrence of 
atherosclerosis (Roman and Salmon, 
2007; Georgiadis et al., 2006). LDL 
subtypes reduction observed and this 
study after the administration of anti-
TNFα treatment. On the other hand, a 
decrease of HDL3a and HDL3c 
subtypes observed with the same 
treatment. Recent studies suggest that 
decrease of HDL subtypes generally 
lead to an increased concentration of 
triglyceride-rich lipoproteins in plasma 
and therefore increase atherosclerosis 
risk. Hence, HDL concentration must 
be considered in relation to LDL 
(Parhofer, 2015). 
This study is the first effort to define 
the anti-TNFα activate on lipoproteins 
and thus on the progression of 
cardiovascular disease in patients 
suffering from rheumatoid arthritis. 
The results show that anti-TNFα 
administration can lower the risk of 
atherosclerosis as it reduces the LDL 
subtypes which have been linked with 
atherosclerosis and other 
cardiovascular diseases.   
It should be noted that changes in 
lipoprotein subtypes can also be 
influenced by the dietary habits of 
patients. Alcohol, smoking, exercise, 
and eating habits may be related to 
some of the lipoprotein changes 
observed in this study. These factors 
were not defined in this study 
(Kotsovasilis and Bei, 2003).  
In conclusion, administration of anti-
TNFα drugs can change the lipoprotein 
subtype pattern in reumatoid arthritis 
patients. It can also be protective to 
those patients due to the reduction of 
LDL subtypes since LDL subtypes are 
linked to a higher risk of 
atherosclerosis.  
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